Navigation Links
Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production
Date:12/2/2009

s defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release and the section under "Financial Outlook" contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incid
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
4. Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
5. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
6. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
8. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
9. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Improved Long-term [Five-years],Overall Survival for these Seriously ... -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, provided significant,improvements ... and,time to disease progression (TTP) - a ... with metastatic (advanced) colorectal cancer.,Importantly, the FOLFOX4 ...
... Presented at Society of Nuclear,Medicine Annual Meeting ... Inc. , a biopharmaceutical company focused on,developing ... serious,diseases, today announced that its anti-carcinoembryonic antigen,(CEA) ... found to be safe and active when ...
Cached Medicine Technology:Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2
... ... for the treatment of acute injuries and chronic conditions affecting soft tissues, such as ... ... Therapy, a leading provider of physical medicine and rehabilitation services in the metropolitan New ...
... Arizona criminal attorney ... case of State v. Norton. The Downtown Justice Court suppressed Norton,s breath alcohol readings of ... Phoenix, ... was able to get the breath alcohol readings suppressed in the case of State V. ...
... Moderate Traumatic Brain Injury (TBI) today released the following statement regarding Brain Injury Awareness Month: , ... , , ... ... "BHR Pharma ...
... March 23 Healthcare organizations looking to reduce costs and improve patient care by extending their information management to the mobile world can now do so without undergoing ... ... ... ...
... secure and trusted environment using MobiSecure® SMS, a new product introduced today by Diversinet Corp. (OTC Bulletin Board: DVNTF; TSX Venture: DIV). , ... , ... ... ...
... be harder to lie about your age or your poker ... has revealed that our eye position betrays the numbers we ... asked to state a series of random numbers. By measuring ... predict with reliable confidence the next chosen number - before ...
Cached Medicine News:Health News:New York Sports Medicine Offers Platelet Rich Plasma Therapy For Treatment of Injury 2Health News:New York Sports Medicine Offers Platelet Rich Plasma Therapy For Treatment of Injury 3Health News:Arizona Criminal Attorney Gets Breath Alcohol Readings Suppressed 2Health News:BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now 2Health News:BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now 3Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 2Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 3Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 4Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 5Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 6Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 7Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 2Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 3Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 4Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 5Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 6Health News:Our eye position betrays the numbers we have in mind, new study 2
This legless table has adjustable height and round post. Pad sold separately....
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
This table has adjustable height, round post, and universal clamp. Replacement 1" (5 cm) or 2" (2.5 cm) pad sold separately....
... An excellent choice for orthopedic procedures. ... width to 24" for the ... clamps quickly attach to any O.R. ... easy C-Arm access and stability. ...
Medicine Products: